Our previous work under the RMRCE demonstrates that immunological protection against a Francisella tularensis infection can be elicited with an acellular vaccine, and in particular, a membrane preparation from this bacterium admixed with an adjuvant inducing a Th1 response is required to generate a protective adaptive immune response. Further, the level of protection elicited by a specific antigen preparation can be dramatically altered based on the adjuvant and route of delivery. Thus, tools are available to assess more precisely the innate and adaptive responses required for protection against F. tularensis. The humoral and cellular immune responses are both required to achieve optimal protection, with a B1b cell mediated IgM response being of greatest importance for early (3 days post-vaccination) protective immunity. These data along with the observation that the membrane protein fraction (MPF) admixed with the CLDC adjuvant stimulates inactivated macrophages to clear virulent F. tularensis leads us to hypothesize that surface structures of F. tularensis are critical targets for vaccine development and that stimulation of the proper innate response and T cell independent humoral immunity against surface structures can be exploited for a therapeutic vaccine to augment standard antibiotic treatment against F. tularensis and prevent relapse. To further these studies we will 1) identify F. tularensis surface proteins and non-protein structures that are targets for vaccine and therapeutic development;2) elucidate protective immune responses elicited by adjuvant complexed accellular preparations and LVS vaccination;and 3) assess therapeutic vaccination to augment conventional chemotherapeutic treatment of tularemia and prevent relapse. This research project fits within the RMRCE Integrated Research Focus on Immunomodulation, Adjuvants and Vaccines, and will interact directly with RP1.2 and utilize the resources of Cores E and F.
The work proposed in the application will provide detailed information allowing the development of an acellular vaccine against tularemia. Further, these efforts will demonstrate whether therapeutic vaccination augments standard chemotherapy against an acute bacterial infection and can prevent relapse. Such an approach would have broad implications to the treatment of infections by highly virulent bacterial pathogens.
|Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450|
|Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:|
|Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463|
|Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:|
|Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002|
|Rhodes, Katherine A; Schweizer, Herbert P (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82-90|
|Lehman, Stephanie S; Mladinich, Katherine M; Boonyakanog, Angkana et al. (2016) Versatile nourseothricin and streptomycin/spectinomycin resistance gene cassettes and their use in chromosome integration vectors. J Microbiol Methods 129:8-13|
|Rico, Amber B; Phillips, Aaron T; Schountz, Tony et al. (2016) Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology 499:30-39|
|Calvert, Amanda E; Dixon, Kandice L; Piper, Joseph et al. (2016) A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res 131:92-9|
|Westover, Jonna B; Sefing, Eric J; Bailey, Kevin W et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-8|
Showing the most recent 10 out of 253 publications